2024 annual financial data
Kyverna Therapeutics 2024 Operating income growth
Direct answer
Operating income growth was -128.51%.
Operating income was -142,604,000 USD and net income was -127,477,000 USD.
Operating cash flow was -114,250,000 USD.
Get free Kyverna Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -142,604,000 USD
- Net income
- -127,477,000 USD
- Operating cash flow
- -114,250,000 USD